Results 51 to 60 of about 1,359 (188)
Clinical management of neurogenic orthostatic hypotension
Annals of Movement Disorders, 2019 Neurogenic orthostatic hypotension is a common disorder often seen in elderly patients affected with neurodegenerative disorders and peripheral neuropathies.
Malligurki Raghurama Rukmani +3 more
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background Neurogenic orthostatic hypotension, a sustained decrease in blood pressure upon standing, is caused by autonomic nervous system failure and characterized by an insufficient increase in heart rate needed to maintain blood pressure upon standing.
Sameh K. Mobarek
doaj +1 more source
Cardiology and Therapy, 2019 Introduction The prevalence of neurogenic orthostatic hypotension (nOH) increases with age and is associated with autonomic failure in neurodegenerative diseases (e.g., Parkinson's disease).
Peter A. McCullough
doaj +1 more source
Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension [PDF]
The American Journal of Cardiology, 2017 The norepinephrine prodrug droxidopa improves symptoms of neurogenic orthostatic hypotension, a condition that is associated with diseases of neurogenic autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure). These conditions are more prevalent in older patients who also have cardiovascular co-morbidities.
Adam Ziemann +4 more
openaire +3 more sources
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension [PDF]
Neurology, 2018 To test whether the plasma levels of norepinephrine (NE) in patients with neurogenic orthostatic hypotension (nOH) predict their pressor response to droxidopa.This was an observational study, which included patients with nOH. All patients had standardized autonomic function testing including determination of venous plasma catecholamine levels drawn ...
Jose‐Alberto Palma +3 more
openalex +4 more sources
Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease [PDF]
Clinical Autonomic Research, 2017 Daniel O. Claassen, Mark Lew
openalex +3 more sources
Method development and validation of droxidopa by HPLC technique
International Journal of Research in Pharmaceutical Sciences, 2020 The purpose of this work is to develop and validate stability, indicating reverse phase High-performance liquid chromatography (HPLC) method for the rapid and precise determination of droxidopa in its pure form and formulations. A simple, fast, accurate and economical way has been developed and validated for the quantification of droxidopa by HPLC ...
Nalini C N +3 more
openaire +2 more sources
Journal of Parkinson’s Disease, 2014 Background: Neurogenic orthostatic hypotension (nOH) is common in Parkinson's disease (PD), and represents a failure to generate norepinephrine responses appropriate for postural change. Droxidopa (L-threo-3,4-dihydroxyphenylserine) is an oral norepinephrine prodrug.
Robert A. Hauser +2 more
openalex +5 more sources
Blood, 2021 Background Orthostatic hypotension due to autonomic dysfunction is a well-known complication of light chain (AL) amyloidosis, which can become progressively debilitating and difficult to manage.
Jorge Nicolas Ruiz Lopez +6 more
semanticscholar +1 more source
Movement Disorders, EarlyView.Abstract Background Central synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), involve alpha‐synuclein accumulation and dopaminergic cell loss in the substantia nigra (SN) and locus coeruleus (LC).
Paula Trujillo +10 more
wiley +1 more source